Date

Monday, May 10, 2021

Venue

Auditorium - Omni Hospital, Pulomas 7th floor, West Pulomas St VI No. 20, East Jakarta 13210

Time

09:30 (GMT+7)

Agenda

AGMS

  1. Approval (a) of the Annual Report, including the ratification of the Financial Statements, and the Board of Commissioners Oversight Report of the financial year 2020, and to release and discharge of all responsibilities (volledig acquit et de charge) to all Board members for the management and supervision carried out in the financial year 2020, as long as it is reflected in the Annual Report and recorded in the company's Financial Statements and (b) approval related to the reporting of the company's Limited Public Offering I 2021 in accordance with the Financial Services Authority Regulation ("OJK") No. 30/POJK.04/2015 regarding the Proceeds usage report from Public Offering ("POJK No. 30/2015").
  2. Approval of Determination on the use of the company net profit of the financial year 2020.
  3. Approval on the delegation to Board of Commissioners to determine salary and honorarium and/or other benefits for all Board members in 2021.
  4. Approval of the Election of a Public Accountant Firm to audit the company Financial Report of the financial year 2021, and authorise Board of Directors of the company to determine the honorarium of the Public Accountant and other requirements.
  5. Approval of adjustments to the company's Articles of Association related to OJK Regulation No. 15/POJK.04/2020 regarding the plan and implementation of General Meeting of Shareholders of Public Companies ("POJK No. 15/2020").

EGMS

  1. Approval of amendments to the provisions of Article 4 of the company's Articles of Association related to the increase in the company’s authorised capital.
  2. Approval of the company's plan to increase capital with Pre-emptive Rights (“HMETD”) to the shareholders through limited public offering with HMETD based on OJK Regulation No. 32/POJK.04/2015 regarding the Capital Increase with Providing Pre-emptive Rights as amended by OJK Regulation No. 14/POJK.04/2019 (“POJK No. 32/2015”).
  3. Approval of amendments to the provisions of Article 4 of the company's Articles of Association, in relation to Preemptive Rights, including changes in the company’s issued and paid-up capital.
  4. Approval of the company's plan to take over 99.9999% shares of PT Elang Medika Corpora ("EMC") owned by PT Elang Mahkota Teknologi Tbk ("EMTK") related to the fulfillment of the provisions of the company’s regulation, which is a Material Transaction as referred in the OJK Regulation No. 17/POJK.04/2020 regarding Material Transactions and changes in Business Activities ("POJK No. 17/2020").
  5. Approval of the company's plan to take over 99.9999% of EMC's shares owned by EMTK, which is an Affiliated Transaction as referred in OJK Regulation No. 42/2020, and is also an Affiliated Transaction and Conflict of Interest Transaction ("POJK No. 42/2020") as referred in POJK No. 17/2020.
  6. Approval to guarantee most or all of the company’s assets and/or subsidiaries, including but not limited to the provision of corporate guarantees to be provided by the Company and/or its subsidiaries to banks and/or the other financial institutions related to the financing plan from banks and/or the other financial institutions as required by the provisions of Article 102 of the company’s regulation.

(W)

来源:
来源 #1
SAME - PT. Sarana Meditama Metropolitan Tbk

Rp 464

-16 (-3,45%)